|
Index | - | P/E | - | EPS (ttm) | - | Insider Own | 23.10% | Shs Outstand | 10.06M | Perf Week | -10.00% |
Market Cap | 42.56M | Forward P/E | - | EPS next Y | -1.50 | Insider Trans | 0.00% | Shs Float | - | Perf Month | -25.53% |
Income | - | PEG | - | EPS next Q | -0.56 | Inst Own | 38.73% | Short Float | - | Perf Quarter | 1.93% |
Sales | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.18 | Perf Half Y | -13.67% |
Book/sh | - | P/B | - | EPS next Y | 26.50% | ROA | - | Target Price | - | Perf Year | - |
Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 3.82 - 7.85 | Perf YTD | -5.37% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -48.54% | Beta | - |
Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | 5.76% | ATR | 0.44 |
Employees | 1 | Current Ratio | - | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 36.17 | Volatility | 5.16% 8.71% |
Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.26 | Prev Close | 4.23 |
Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 206.57K | Price | 4.04 |
Recom | 2.00 | SMA20 | -13.14% | SMA50 | -22.45% | SMA200 | -17.89% | Volume | 38,931 | Change | -4.49% |
![]() | ||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel. | ||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite